Monoclonal antibodies have been applied clinically to the diagnosis and therapy of an array
of human disorders, including cancer and infectious diseases, and have been used for the …

Antibodies with two distinet binding specificities have great potential for a wide range of
clinical applications as targeting agents for in vitro and in vivo immunodiagnosis and …

A humanized IgG antibody to CAMPATH‐1 antigen (CDw52) is known to be lympholytic both
in vitro and in vivo. So as to improve therapeutic potency through protein engineering …

Interactions between human IgG with human FcγRI and FcγRIIa (R131) were studied to
investigate the role of the hinge region of IgG3 and IgG1 in the binding of the antibodies to …

Clearer evidence for immune surveillance in malignancy and the identification of many new
tumour-associated antigens (TAAs) have driven novel vaccine and antibody-targeted …

The rat monoclonal antibody (mAb) YTH12. 5, specific for the CD3 antigen complex on
human T cells has been modified in order to improve its efficacy in human therapy. With the …

Methods of delivering agents to target cells including meth ods of immunotherapy, are
disclosed in Which monospeci? c binding proteins are administered to a host and bind to …

Immunoglobulins, or antibodies, are monospecific, bivalent antigen-binding molecules.
Bifunctional antibodies are bispecific, with each arm binding to a different antigen, and may …

Recent years have shown a tremendous increase and diversification in antibody-based
therapeutics with advances in production techniques and formats. The plethora of currently …

CD3, 4 (anti-CD3: anti-CD4) bispecific monoclonal antibodies (BSMAB) cause a profound
decrease in CD4+ T cells and a marked proliferation of CD8+ T cells in peripheral blood …